- Home
- BELFA vs RCUS Comparison
BELFA vs RCUS Comparison
Compare BELFA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BELFA | RCUS |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BELFA | RCUS |
|---|---|---|
| Price | $189.26 | $18.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 77.6K | ★ 2.2M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,611,000.00 | $247,000,000.00 |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $8.46 | N/A |
| P/E Ratio | $40.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $114.02 | $17.43 |
| 52 Week High | $293.51 | $31.74 |
Technical Indicators
Market Signals| Indicator | BELFA | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 29.48 |
| Support Level | $174.72 | $17.97 |
| Resistance Level | $211.83 | $24.80 |
| Average True Range (ATR) | 7.84 | 1.65 |
| MACD | 2.22 | -0.25 |
| Stochastic Oscillator | 90.25 | 8.46 |
Price Performance
Historical ComparisonAbout BELFA Bel Fuse Inc.
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.